Primary Immunodeficiency (PID)
ASCIA has significantly expanded its range of information for health professionals and patients on Primary Immunodeficiency (PID) since 2014, including the ASCIA Transplantation and PID (TAPID) Project, development of resources to support the use of subcutaneous immunoglobulin (SCIg) and a dedicated webpage www.allergy.org.au/immunodeficiency
ASCIA TAPID Project
The ASCIA TAPID (Transplantation And PID) project is an important and ongoing collaboration between clinical immunologists, transplant physicians and international PID experts, facilitated by ASCIA. The main objective of the TAPID project is to have regular collaborations and discussions between immunologists and transplant physicians in major centres that transplant patients with PIDs in Australasia. TAPID meetings enable complex PID and transplantation cases to be discussed in a confidential expert forum.
At the ASCIA PID (APID) Consultants Meeting in May 2013 the concept of the TAPID (transplantation and PID) project was initiated. Since then:
TAPID face to face meetings have been held in February 2014, May 2017 and May 2018
The TAPID project membership has increased from 12 to more than 90 members
TAPID teleconferences are now held each month
The TAPID project has been supported by unrestricted educational grants from CSL Behring.
Current TAPID members
ASCIA Immunodeficiency (ID) Register
The objectives of this project are to:
- Collect data on all patients with primary immune deficiency diseases in Australia and New Zealand.
- Enhance research, therapies and advocacy for primary and secondary immune deficiencies.
This project is supported by unrestricted educational grants from CSL Behring and Octapharma.
The estimated completion date for this project is mid 2018.
Updated August 2018